steroids

Nasdaq

Biotech

Lyra Therapeutics wants a $58M IPO

Ear, nose and throat diseases biotech Lyra Therapeutics aims to drive through the coronavirus market volatility and gun for a $58 million IPO.

Ben Adams Mar 9, 2020 8:25am

Green traffic light

Spruce nets $88M to push rare disease drug into late-stage trial

Feb 20, 2020 9:55am

DNA

Spruce scores phase 2a win for rare disease drug, preps for 2020

Sep 19, 2019 8:00am